SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up

Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.
Open original source
Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.
Open original source